| Author | Oliveira-Neto, Manoel Paes de | |
| Author | Mattos, Marise | |
| Author | Pirmez, Claude | |
| Author | Fernandes, Octavio | |
| Author | Gonçalves-Costa, Sylvio Celso | |
| Author | Souza, Celeste de Freitas Silva de | |
| Author | Grimaldi Junior, Gabriel | |
| Access date | 2016-09-15T17:57:51Z | |
| Available date | 2016-09-15T17:57:51Z | |
| Document date | 2000 | |
| Citation | OLIVEIRA-NETO, Manoel Paes de et al. Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime ®) in Rio de Janeiro, Brazil. Revista do Instituto de Medicina Tropical de São Paulo, v. 42, n. 6, p. 321-325, Nov./Dec. 2000. | pt_BR |
| ISSN | 1678-9946 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/15822 | |
| Language | eng | pt_BR |
| Publisher | Instituto de Medicina Tropical de São Paulo | pt_BR |
| Rights | open access | |
| Title | Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime ®) in Rio de Janeiro, Brazil | pt_BR |
| Alternative title | Leishmaniose mucosa ("espundia") respondendo a baixa dose de N-metil-glucamina (Glucantime ®) no Rio de Janeiro, Brasil | |
| Type | Article | |
| DOI | 10.1590/S0036-46652000000600004 | |
| Abstract | Response to treatment with antimonial drugs varies considerably depending on the parasite strain involved, immune status of the patient and clinical form of the disease. Therapeutic regimens with this first line drug have been frequently modified both, in dose and duration of therapy. A regimen of 20 mg/kg/day of pentavalent antimony (Sb5+) during four weeks without an upper limit on the daily dose is currently recommended for mucosal disease ("espundia"). Side-effects with this dose are more marked in elderly patients, more commonly affected by this form of leishmaniasis. According to our experience, leishmaniasis in Rio de Janeiro responds well to antimony and, in cutaneous disease, high cure rates are obtained with 5 mg/kg/day of Sb5+ during 30 to 45-days. In this study a high rate of cure (91.4%) employing this dose was achieved in 36 patients with mild disease in this same geographic region. Side-effects were reduced and no antimony refractoriness was noted with subsequent use of larger dose in patients that failed to respond to initial schedule. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Medicina Tropical. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Protozoologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Protozoologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Protozoologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Subject | Mucosal leishmaniasis | pt_BR |
| Subject | Leishmania (Viannia) braziliensis | pt_BR |
| Subject | Antimony | pt_BR |
| Subject | Therapy | |
| e-ISSN | 1678-9946 | |
